Safety, effectiveness and exposure-response of micafungin in infants

Application of an established pharmacokinetics model to electronic health records

Nazario D. Rivera-Chaparro, Jessica Ericson, Huali Wu, P. Brian Smith, Reese H. Clark, Daniel K. Benjamin, Michael Cohen-Wolkowiez, Rachel G. Greenberg

Research output: Contribution to journalArticle

Abstract

Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.

Original languageEnglish (US)
Pages (from-to)e26-e28
JournalPediatric Infectious Disease Journal
Volume38
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Electronic Health Records
Pharmacokinetics
Safety
Invasive Candidiasis
Biomarkers
Newborn Infant
Liver
micafungin

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Rivera-Chaparro, Nazario D. ; Ericson, Jessica ; Wu, Huali ; Smith, P. Brian ; Clark, Reese H. ; Benjamin, Daniel K. ; Cohen-Wolkowiez, Michael ; Greenberg, Rachel G. / Safety, effectiveness and exposure-response of micafungin in infants : Application of an established pharmacokinetics model to electronic health records. In: Pediatric Infectious Disease Journal. 2019 ; Vol. 38, No. 2. pp. e26-e28.
@article{c10885ed71f9428183bea9a50cc7482a,
title = "Safety, effectiveness and exposure-response of micafungin in infants: Application of an established pharmacokinetics model to electronic health records",
abstract = "Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.",
author = "Rivera-Chaparro, {Nazario D.} and Jessica Ericson and Huali Wu and Smith, {P. Brian} and Clark, {Reese H.} and Benjamin, {Daniel K.} and Michael Cohen-Wolkowiez and Greenberg, {Rachel G.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1097/INF.0000000000002045",
language = "English (US)",
volume = "38",
pages = "e26--e28",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Safety, effectiveness and exposure-response of micafungin in infants : Application of an established pharmacokinetics model to electronic health records. / Rivera-Chaparro, Nazario D.; Ericson, Jessica; Wu, Huali; Smith, P. Brian; Clark, Reese H.; Benjamin, Daniel K.; Cohen-Wolkowiez, Michael; Greenberg, Rachel G.

In: Pediatric Infectious Disease Journal, Vol. 38, No. 2, 01.02.2019, p. e26-e28.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety, effectiveness and exposure-response of micafungin in infants

T2 - Application of an established pharmacokinetics model to electronic health records

AU - Rivera-Chaparro, Nazario D.

AU - Ericson, Jessica

AU - Wu, Huali

AU - Smith, P. Brian

AU - Clark, Reese H.

AU - Benjamin, Daniel K.

AU - Cohen-Wolkowiez, Michael

AU - Greenberg, Rachel G.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.

AB - Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.

UR - http://www.scopus.com/inward/record.url?scp=85059883824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059883824&partnerID=8YFLogxK

U2 - 10.1097/INF.0000000000002045

DO - 10.1097/INF.0000000000002045

M3 - Article

VL - 38

SP - e26-e28

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 2

ER -